Krystal Biotech announced $116.4 million in global revenue for Q1 2026, a 32% increase year-over-year, driven by its gene therapy product VYJUVEK for dystrophic epidermolysis bullosa. The company completed enrollment in a key registrational study for KB803 and expects data readouts for KB803 and KB801 later in 2026. The FDA granted platform technology designations for KB407 and KB111, potentially accelerating development. Krystal ended the quarter with $1 billion in cash and investments, supporting ongoing trials and global expansion efforts.
Funnel has introduced Digital Measurement, a new marketing mix modeling (MMM) software that integrates MMM, Multi-Touch Attribution (MTA), and ad platform signals into one calibrated system. This approach addresses the limitations of relying on a sin...
Zealand Pharma held an Extraordinary General Meeting on May 26, 2026, where all proposals were approved, including the election of Camilla Sylvest to the Board of Directors. The board now consists of seven shareholder-elected members and four employe...
Nvidia has been a top AI investment as demand for AI chips surged, but the next wave of IPOs from major AI customers like SpaceX, OpenAI, and Anthropic could shift investor focus. These companies, while not competitors in hardware, may compete for in...
Salazar Resources announced a new copper-gold porphyry system discovery at its 100%-owned Monja Project in southern Ecuador, featuring high-grade surface samples. This discovery comes as global copper prices hit record highs due to supply deficits, i...
Novee has introduced Agentic Fix, an enhancement to its AI penetration testing platform that automates the transition from identifying security vulnerabilities to deploying fixes. This tool generates detailed remediation guidance based on validated e...
